Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Sep 23, 2024 4:44pm
161 Views
Post# 36237155

Where is Matt, he is off sick, learn to read

Where is Matt, he is off sick, learn to read

The question concerning " where's Matt"?

Quite frankly a useless distraction.
They ( Onc mangement & B.O.D ) put in place a substitute power of attorney , prior to his announced medical  leave.
Understand, Matt did the original study on Pela , discovered in 1998/99, that the virus onky replicates in cancer cells.
Meaning it can be administered I.V. : does not need to be intertumoural. It finds the cancer!
He went on, with colegues to firm oncolytics biotech.
One mission, to prove efficacy & get it to market as a cancer treatment.
For Matt to be away from his life's work is a very serious situation.
Meaning he is not at all well.
They did put in place the legal POA, 
The science side?
Sufice to day, the trials in co- therapy , within the last 5+ years are not managed by Onc at all.
Yes they provide funding, guidance etc. agencies such as SOLTI, CGAR & with lots of input from Roche.run the trials.....at mutiple institutions across the globe.
The most recent and strongest outcome is with Roche p, within the goblet trial, for pancreatic cancer.
Yes they did prove efficacy, actually 3x better  than the inplace standard of care.
That is why they were granted $5million to add an additional arm. AND, strong support & colaborations with CGAR to run the modified phase 3 trial ASAP.
Yes a lot of time was lost determining Pela to be working as a priming co- theraoy & not a mono- lysis treatement.
Drug Development is like that. Very risky, many unknowns. I'll refer to thylidamide as an example.
stepping out of one's skin is a hard way to view the world & others.
Easy to throw stones & insults. I do ask the question, Could you have done better?
Matt is off sick. He left Onc in as best possible position to carry on.
like us, he is a person & deserves respect 

 

<< Previous
Bullboard Posts
Next >>